American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 935-944 , November 2009

Induction Antibody Therapy in Kidney Transplantation

Received 17 February 2009 ,Accepted 9 June 2009.

References 

  1. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256–3262
  2. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIg desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346–351
  3. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3:1017–1022
  4. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant. 2004;8:535–542
  5. Tyden G, Kumlein G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy using antigen specific immunoadsorption and rituximab. Am J Transplant. 2005;5:145–148
  6. Schwartz J, Stegall MD, Kremers WK, et al. Complications, resource utilization and cost of ABO-incompatible living donor kidney transplantation. Transplantation. 2006;82:155–163
  7. Wechter WJ, Brodie JA, Morell RM, Rafi M, Schultz JR. Antithymocyte globulin (Atgam) in renal allograft recipients: Multicenter trials using a 14-day regimen. Transplantation. 1979;28:294–302
  8. Dell PRF, Blamey RW, Briggs JD, et al. Medical Research Council trial of antilymphocyte globulin in renal transplantation: A multicenter randomized double-blind placebo controlled clinical investigation. Transplantation. 1983;35:539–545
  9. Mourad G, Gariigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72:1050–1055
  10. Belitsky P, MacDonald AS, Lawen J, et al. Use of rabbit anti-thymocyte globulin for induction immunosuppression in high-risk kidney transplant recipients. Transplant Proc. 1997;29(suppl 7A):S16–S17
  11. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977
  12. Gaston RS, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation. 1992;53:103–109
  13. Augustine JJ, Poggio ED, Heeger PS, Hricik DE. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation. 2008;86:529–534
  14. Szczech LA, Berlin JA, Aradhye S, et al. Effect of antilymphocyte induction on renal allograft survival: A meta-analysis. J Am Soc Nephrol. 1997;8:1771–1777
  15. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993;55:44–50
  16. Abramowicz D, Goldman M, DePauw L, Vanherweghem JL, Kinnaert P, Vereerstraeten P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation—A single center, prospective, randomized study. Transplantation. 1992;54:433–437
  17. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323:1723–1728
  18. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A Collaborative Transplant Study report. Am J Transplant. 2003;4:222–230
  19. Bloom DD, Hu H, Fechner JH, et al. T-Lymphocyte alloresponses of Campath 1-H treated kidney transplant patients. Transplantation. 2006;81:81–87
  20. Calne R, Moffatt SD, Friend PJ, et al. Campath 1 H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68:1613–1616
  21. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation. 2003;76:120–129
  22. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005;200:505–515
  23. Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant. 2009;9:355–366
  24. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation—Efficacy and safety at five years. Am J Transplant. 2005;5:1347–1353
  25. Barth RN, Janus CA, Lilesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int. 2006;19:885–892
  26. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant. 2005;5:3009–3014
  27. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab—Long term results. Am J Transplant. 2005;5:2539–2548
  28. Ciancio G, Burke G, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil and steroid sparing and newer immune monitoring. Transplantation. 2005;80:457–465
  29. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–2625
  30. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation (The U.S. Simulect Renal Transplant Study Group). Transplantation. 1999;68:1288–1294
  31. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant. 2002;2:568–573
  32. ter Meulen CG, Baan CC, Hené RJ, et al. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation. 2001;72:1709–1710
  33. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients (CHIB 201 International Study Group). Lancet. 1997;350:1193–1198
  34. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody (United States Simulect Renal Study Group). Transplantation. 1999;67:276–284
  35. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003;75:37–43
  36. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 2001;72:1261–1267
  37. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab (Daclizumab Double Therapy Study Group). Transplantation. 1999;67:110–115
  38. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation (Daclizumab Triple Therapy Study Group). N Engl J Med. 1998;338:161–165
  39. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ. 2003;326:789–793
  40. Sollinger H, Kaplan B, Pescovitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation. 2001;72:1915–1919
  41. Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002;2:48–56
  42. Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med. 2008;359:1736–1738
  43. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577
  44. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575
  45. Gelens MA, Christiaans MH, van Heurn EL, et al. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation. 2006;82:1221–1223
  46. Cosimi AB, Skamene E, Bonney WW, Russell PS. Experience with large dose intravenous antithymocyte globulin in primates and man. Surgery. 1970;68:54–61
  47. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67:1011–1018
  48. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus Atgam induction in adult renal transplantation. Transplantation. 2004;78:136–141
  49. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy: 10 Year results. Transplantation. 2008;86:947–952
  50. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003;76:798–802
  51. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002;73:473–475
  52. Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73:1514–1518
  53. Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19:629–635
  54. Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008;85:1425–1430
  55. Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: An interim report. Transplantation. 2008;85:1391–1399
  56. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6:1111–1131
  57. Salmela K, Wrammer L, Ekberg H, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimoab) for the prevention of acute rejection and delayed graft function in cadaveric renal transplantation. Transplantation. 1999;67:729–733
  58. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantation. Transplantation. 1996;62:1565–1570
  59. Vinceti F, Mendez R, Pesovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7:1770–1777

 Originally published online as doi: 10.1053/j.ajkd.2009.06.020 on August 17, 2009.

PII: S0272-6386(09)00937-8

doi: 10.1053/j.ajkd.2009.06.020

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 935-944 , November 2009

Article Tools

* Image Usage & Resolution